Quick Answer
PharmaCyte Biotech, Inc. reported Stockholders Equity of $51.89 million for the year ending 2025.
- PharmaCyte Biotech, Inc. showed an increase of +87.7% in Stockholders Equity from 2024 to 2025.
- This data is from PharmaCyte Biotech, Inc.'s annual report (Form 10-K), filed with the SEC on August 11, 2025.
- XBRL data for this metric is available from 2010 to 2025 (16 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2014: $7.83 million | Q4 2014: $6.38 million | Q1 2015: $6.25 million | Q3 2015: $6.96 million | Q4 2015: $6.56 million | Q1 2016: $6.94 million | Q4 2016: $6.28 million | Q3 2017: $8.66 million | Q4 2017: $7.35 million | Q1 2018: $5.84 million | Q3 2018: $6.20 million | Q4 2018: $5.40 million | Q1 2019: $5.37 million | Q3 2019: $5.00 million | Q4 2019: $4.53 million | Q1 2020: $4.32 million | Q3 2020: $6.25 million | Q4 2020: $8.28 million | Q1 2021: $7.61 million | Q3 2021: $5.71 million | Q4 2021: $92.12 million | Q1 2022: $91.33 million | Q3 2022: $86.30 million | Q4 2022: $81.04 million | Q1 2023: $77.12 million | Q3 2023: $39.19 million | Q4 2023: $36.77 million | Q1 2024: $31.37 million | Q2 2024: $27.65 million | Q3 2024: $47.71 million | Q4 2024: $43.45 million | Q1 2025: $40.25 million | Q2 2025: $51.89 million | Q3 2025: $43.59 million | Q4 2025: $35.24 million | Q1 2026: $38.11 million.
- Over the full 16 years of available data (2010 to 2025), PharmaCyte Biotech, Inc.'s Stockholders Equity has grown by 2,217.0%.
- Historical annual values: Fiscal year 2025: $51.89 million | Fiscal year 2024: $27.65 million | Fiscal year 2023: $72.69 million | Fiscal year 2022: $89.92 million | Fiscal year 2021: $6.68 million | Fiscal year 2020: $5.09 million | Fiscal year 2019: $5.04 million | Fiscal year 2018: $5.77 million | Fiscal year 2017: $8.09 million | Fiscal year 2016: $6.52 million | Fiscal year 2015: $7.78 million | Fiscal year 2014: $8.94 million | Fiscal year 2013: -$1.50 million | Fiscal year 2012: -$2.28 million | Fiscal year 2011: -$2.73 million | Fiscal year 2010: -$2.45 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: